Stay updated with breaking news from For aflibercept. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The letter makes reference to an ongoing review of inspection findings from a third-party filler involved with the drug development. Regeneron will not require additional trial data. ....